Transgenic models have been used to support COVID-19 studies, but have been associated with some limitations, such as the non-physiological expression of the hACE2 transgene and the inability to accurately model mild to moderate forms of the disease.
To address these shortcomings, our team at Inotiv used CRISPR-Cas9 technology to develop humanized ACE2 (hACE2) knockin rats (Hsd:SD-Ace2em1(ACE2)Env). We then partnered with scientists at Kansas State University to research the model and confirmed that:
• hACE2 rats can serve as a superior model to existing transgenic models for investigating the pathogenesis of SARS-COV-2
• hACE2 rats display less severe disease than other transgenic models, making them ideal to support “long COVID” studies
Complete the form to review the full details and data in our white paper.
